Last updated: 2026-09-09 04:54:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Dianthus Therapeutics, Inc. (DNTH) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $109.16, with a market capitalization of $6.05B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $25.00 to $117.88. This page covers its latest market performance, valuation, price trends and company information.
$6.05B | |
$105.61 | |
$117.88 | |
$6.58 | |
$108.10 | |
482.95K | |
1.02M | |
-- | |
$117.88 | |
$25.00 | |
-- | |
-- |
Dianthus Therapeutics, Inc. (DNTH) last closed at $108.10 as of 2026-09-08 23:31:00, unchanged from the previous close of $108.10.
During the latest regular trading session, DNTH traded between $6.58 and $117.88, with a volume of 482.95K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Dianthus Therapeutics, Inc. (DNTH) moved from $111.54 to $109.16, representing a decline of 2.13% ($2.38).
The stock traded between $102.38 and $112.13 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 510.44 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.6%
DNTH is currently trading at $109.16, placing it 90.6% of the way from its 52-week low of $25.00 to its 52-week high of $117.88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 92 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Dianthus Therapeutics, Inc. (DNTH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.